Compare Otis Worldwide Corp (OTIS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Smith & Nephew plc — how do they compare? Otis Worldwide Corp trades at $69.36 (market cap $26.67B), while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: Otis Worldwide Corp is far larger — about 2.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| OTIS | SNN | |
|---|---|---|
Market Cap | $26.67B | $11.63B |
Sector | Industrials | Health |
52-Week High | $93.62 | $38.53 |
52-Week Low | $69.30 | $27.80 |
Enterprise Value | $34.70B | $14.66B |
Dividend Yield | 2.51% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide (OTIS) trades at $70.06, down 1.61% on the day, amid a bearish technical signal and recent earnings misses. The stock shows a P/E of 18.01 and P/S of 1.83, with strong cash flow from operations of $1.60B in 2025 but a negative net cash flow of -$1.22B. Recent news includes a dividend declaration and new contracts in China, while technical indicators highlight support near $70 and an oversold RSI.
The outlook is mixed: analyst consensus is a Buy with a $92.50 price target, implying upside, but risks include high debt-to-asset ratio of 75.54% and margin pressure from labor costs. Service segment growth offers stability, yet weak new equipment demand and guidance cuts temper near-term optimism.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
